公开(公告)号：US20220062419A1

公开(公告)日：2022-03-03

申请号：US17227753

申请日：2021-04-12

申请人： IMMUNOLIGHT, LLC ,  DUKE UNIVERSITY

发明人： Mark OLDHAM ,  Justus ADAMSON ,  Mark W. DEWHIRST ,  Paul YOON ,  Harold WALDER ,  Frederic A. Bourke, JR. ,  Zakaryae FATHI ,  Wayne F. BEYER, JR.

IPC分类号： A61K41/00 ,  A61N5/06 ,  A61K31/655 ,  A61K33/02 ,  A61K31/409 ,  A61K31/525 ,  A61K31/352 ,  A61K31/403 ,  A61K33/242 ,  A61K33/244 ,  A61K33/24 ,  A61N5/10

摘要： A method and system for treating a subject with a disorder which provides within the subject at least one photoactivatable drug for treatment of the subject, applies initiation energy from at least one source to generate inside the subject a preferential x-ray flux for generation of Cherenkov radiation (CR) light capable of activating at least one photoactivatable drug, and from the CR light, activating inside the subject the at least one photoactivatable drug to thereby treat the disorder.

公开(公告)号：US20190336785A1

公开(公告)日：2019-11-07

申请号：US16511536

申请日：2019-07-15

申请人： IMMUNOLIGHT, LLC ,  DUKE UNIVERSITY

发明人： Tuan VO-DINH ,  Jonathan P. Scaffidi ,  Venkata Gopal Reddy Chada ,  Benoit Lauly ,  Yan Zhang ,  Molly K. Gregas ,  Ian Nicholas Stanton ,  Joshua T. Stecher ,  Michael J. Therien ,  Frederic A. Bourke, JR. ,  Harold Walder ,  Zak Fathi ,  Jennifer A. Ayres ,  Zhenyuan Zhang ,  Joseph H. Simmons ,  Stephen John Norton

IPC分类号： A61N5/06 ,  A61B5/00 ,  A61L2/00 ,  A61K49/00 ,  A61M5/00 ,  A61K41/00 ,  A61N1/40 ,  A61N5/02 ,  A61B6/00 ,  A61B5/055

摘要： Products, compositions, systems, and methods for modifying a target structure which mediates or is associated with a biological activity, including treatment of conditions, disorders, or diseases mediated by or associated with a target structure, such as a virus, cell, subcellular structure or extracellular structure. The methods may be performed in situ in a non-invasive manner by placing a nanoparticle having a metallic shell on at least a fraction of a surface in a vicinity of a target structure in a subject and applying an initiation energy to a subject thus producing an effect on or change to the target structure directly or via a modulation agent. The nanoparticle is configured, upon exposure to a first wavelength λ1, to generate a second wavelength λ2 of radiation having a higher energy than the first wavelength λ1. The methods may further be performed by application of an initiation energy to a subject in situ to activate a pharmaceutical agent directly or via an energy modulation agent, optionally in the presence of one or more plasmonics active agents, thus producing an effect on or change to the target structure. Kits containing products or compositions formulated or configured and systems for use in practicing these methods.

公开(公告)号：US20200222711A1

公开(公告)日：2020-07-16

申请号：US16728803

申请日：2019-12-27

申请人： IMMUNOLIGHT, LLC. ,  DUKE UNIVERSITY

发明人： Harold WALDER ,  Frederic A. Bourke, JR. ,  Zakaryae Fathi ,  Wayne F. Beyer, JR. ,  Mark Dewhirst ,  Mark Oldham ,  Justus Adamson ,  Michael Nolan

IPC分类号： A61N5/06 ,  A61K41/17 ,  A61K39/00 ,  A61K41/00 ,  A61K49/04 ,  A61N5/02 ,  A61N5/10

摘要： A system and method for imaging or treating a disease in a human or animal body. The system provides to the human or animal body a pharmaceutical carrier including one or more phosphors which are capable of emitting ultraviolet or visible light into the body and which provide x-ray contrast. The system includes one or more devices which infuse a diseased site with a photoactivatable drug and the pharmaceutical carrier, an initiation energy source comprising an x-ray or high energy source which irradiates the diseased site with at least one of x-rays, gamma rays, or electrons to thereby initiate emission of said ultraviolet or visible light into the body, and a processor programmed to at least one of 1) produce images of the diseased site or 2) control a dose of said x-rays, gamma rays, or electrons to the diseased site for production of said ultraviolet or visible light at the diseased site to activate the photoactivatable drug.

公开(公告)号：US20180154178A1

公开(公告)日：2018-06-07

申请号：US15819130

申请日：2017-11-21

申请人： IMMUNOLIGHT, LLC. ,  DUKE UNIVERSITY

发明人： Mark Oldham ,  Justus Adamson ,  Paul Yoon ,  Harold Walder ,  Frederic A. Bourke, JR. ,  Zakaryae Fathi ,  Wayne F. Beyer

IPC分类号： A61N5/10 ,  C09K11/59 ,  C09K11/73 ,  A61K41/00 ,  C09K11/02 ,  A61K31/37 ,  A61P35/00

CPC分类号： A61N5/1031 ,  A61K31/37 ,  A61K41/0057 ,  A61K41/0066 ,  A61K49/0423 ,  A61N5/1077 ,  A61N2005/1034 ,  A61N2005/1098 ,  A61P35/00 ,  C09K11/02 ,  C09K11/595 ,  C09K11/73

摘要： A phosphor-containing drug activator activatable from a Monte Carlo derived x-ray exposure for treatment of a diseased site. The activator includes an admixture or suspension of one or more phosphors capable of emitting ultraviolet and visible light upon interaction with x-rays, wherein a distribution of the phosphors in the diseased target site is based on a Monte Carlo derived x-ray dose. A system for treating a disease in a subject in need thereof, includes the drug activator and a photoactivatable drug, one or more devices which infuse the photoactivatable drug and the activator including the pharmaceutically acceptable carrier into a diseased site in the subject; and an x-ray source which is controlled to deliver the Monte Carlo derived x-ray exposure to the subject for production of ultraviolet and visible light inside the subject to activate the photoactivatable drug.

公开(公告)号：US20160243235A1

公开(公告)日：2016-08-25

申请号：US14947255

申请日：2015-11-20

申请人： Duke University ,  Immunolight, LLC

发明人： Tuan VO-DINH ,  Frederic A. Bourke, JR.

IPC分类号： A61K41/00 ,  A61K39/00 ,  A61N5/06 ,  A61K31/37

CPC分类号： A61K41/0061 ,  A61K9/14 ,  A61K9/143 ,  A61K31/37 ,  A61K39/00 ,  A61K41/0028 ,  A61K41/0066 ,  A61K47/52 ,  A61K2039/57 ,  A61N5/06 ,  A61N5/062

摘要： The use of plasmonics enhanced photospectral therapy (PEPST) and exiton-plasmon enhanced phototherapy (EPEP) in the treatment of various cell proliferation disorders, and the PEPST and EPEP agents and probes used therein.

公开(公告)号：US20220226666A1

公开(公告)日：2022-07-21

申请号：US17655683

申请日：2022-03-21

申请人： IMMUNOLIGHT, LLC ,  DUKE UNIVERSITY

发明人： Mark Oldham ,  Zakaryae Fathi ,  Wayne F. Beyer ,  Frederic A. Bourke, JR. ,  Harold Walder ,  Mark Dewhirst ,  Neil L. Spector ,  Paul Yoon ,  Justus Adamson ,  David Alcorta ,  Kim Lyerly ,  Leihua Liu ,  Takuya Osada

IPC分类号： A61N5/06 ,  A61K31/352 ,  A61K41/00

摘要： A method for treating a diseased site in a human or animal body is provided which includes injecting in a diseased site one or more phosphors which are capable of emitting ultraviolet or visible light into the body;
infusing the diseased site with a photoactivatable drug;
applying an initiation energy from an initiation energy source comprising an x-ray, gamma ray, or electron source to thereby initiate emission of ultraviolet or visible light into the body; and
controlling a dose of the initiation energy with a processor to produce (i) a cytotoxicity inside the diseased site of greater than 20% or (ii) a day-25 stable tumor volume,
wherein the processor is programmed to apply the initiation energy in a pulsed manner, wherein the initiation energy is delivered in either (i) a radiograph mode, or (ii) a pulsed fluoroscopy mode.

公开(公告)号：US20180169433A1

公开(公告)日：2018-06-21

申请号：US15876401

申请日：2018-01-22

申请人： Immunolight, LLC ,  Duke University

发明人： Eric J. Toone ,  David Gooden ,  Frederic A. Bourke, JR. ,  Harold Walder

IPC分类号： A61N5/06 ,  A61K39/39 ,  C07D493/04

CPC分类号： A61N5/062 ,  A61K31/37 ,  A61K39/39 ,  A61N5/0601 ,  A61N5/0616 ,  A61N5/10 ,  A61N2005/0612 ,  A61N2005/063 ,  A61N2005/0659 ,  A61N2005/0661 ,  A61N2005/0662 ,  A61N2005/1098 ,  C07D493/04

摘要： Psoralen compounds of compounds having formulae 1A-10A, 1B-10B, 1C-10C, 1D-10D, 1E-10E, 1F-10F, 1G-10G, and 1H-5H as shown in FIG. 1, and pharmaceutically acceptable salts thereof; and their use in methods for the treatment of a cell proliferation disorder in a subject, pharmaceutical compositions containing the psoralen derivatives, a kit for performing the method, and a method for causing an autovaccine effect in a subject using the method.

公开(公告)号：US20170196977A1

公开(公告)日：2017-07-13

申请号：US15469114

申请日：2017-03-24

申请人： DUKE UNIVERSITY ,  IMMUNOLIGHT, LLC

发明人： Tuan VO-DINH ,  Frederic A. Bourke, JR.

IPC分类号： A61K41/00 ,  A61N5/06 ,  A61K39/00 ,  A61K31/37

CPC分类号： A61K41/0061 ,  A61K9/14 ,  A61K9/143 ,  A61K31/37 ,  A61K39/00 ,  A61K41/0028 ,  A61K41/0066 ,  A61K47/52 ,  A61K2039/57 ,  A61N5/06 ,  A61N5/062

摘要： The use of plasmonics enhanced photospectral therapy (PEPST) and exciton-plasmon enhanced phototherapy (EPEP) in the treatment of various cell proliferation disorders, the PEPST and EPEP agents and probes used therein, and pharmaceutical compositions using and/or containing the same.

公开(公告)号：US20190308030A1

公开(公告)日：2019-10-10

申请号：US16295645

申请日：2019-03-07

申请人： IMMUNOLIGHT, LLC. ,  DUKE UNIVERSITY

发明人： Frederic A. Bourke, JR. ,  Tuan Vo-Dinh

IPC分类号： A61N5/06 ,  A61K47/55 ,  A61K31/4427 ,  A61K41/00 ,  A61K31/7056

摘要： The present invention relates to methods for treating cell proliferation disorders comprising: (1) administering to the subject at least one activatable pharmaceutical agent that is capable of activation by a simultaneous two photon absorption event and of effecting a predetermined cellular change when activated; (2) administering at least one plasmonics-active agent to the subject, and (3) applying an initiation energy from an initiation energy source to the subject, wherein the plasmonics-active agent enhances or modifies the applied initiation energy, such that the enhanced or modified initiation energy activates the activatable pharmaceutical agent by the simultaneous two photon absorption event in situ, thus causing the predetermined cellular change to occur, wherein said predetermined cellular change treats the cell proliferation related disorder; and the use of plasmonics enhanced photospectral therapy (PEPST) and exiton-plasmon enhanced phototherapy (EPEP) in the treatment of various cell proliferation disorders, and the PEPST and EPEP agents and probes; a kit and a computer implemented system for performing the method; a pharmaceutical composition useful in the method; and a method for causing an autovaccine effect in a subject using the method.

公开(公告)号：US20170319868A1

公开(公告)日：2017-11-09

申请号：US15649917

申请日：2017-07-14

申请人： IMMUNOLIGHT, LLC. ,  DUKE UNIVERSITY

发明人： Frederic A. Bourke, JR. ,  Harold Walder ,  Zakaryae Fathi ,  Michael J. Therien ,  Mark W. Dewhirst ,  Ian N. Stanton ,  Jennifer Ann Ayres ,  Diane Renee Fels ,  Joseph A. Herbert

IPC分类号： A61N5/06 ,  A61N5/10 ,  A61K41/00

CPC分类号： A61N5/062 ,  A61K41/0085 ,  A61N5/0622 ,  A61N5/1077 ,  A61N2005/0661 ,  A61N2005/1091 ,  A61N2005/1098

摘要： A system and method for light stimulation within a medium. The system has a reduced-voltage x-ray source configured to generate x-rays from a peak applied cathode voltage at or below 105 kVp, and a plurality of energy-emitting particles in the medium which, upon radiation from the x-ray source, radiate at a first lower energy than the x-ray source to interact with at least one photoactivatable agent in the medium. The method introduces the plurality of energy-emitting particles into the medium, radiates the energy-emitting particles in the medium with x-rays generated from a peak applied cathode voltage at or below 105 kVp; and emits a lower energy than the x-ray source to interact with the medium or with at least one photoactivatable agent in the medium.